S&P Futures
4,355.50 -5.50 (-0.13%) Dow Futures
34,183.00 -49.00 (-0.14%) Nasdaq Futures
14,852.50 -17.00 (-0.11%) Russell 2000 Futures
1,789.20 -3.50 (-0.20%) Crude Oil
90.32 +0.29 (+0.32%) Gold
1,941.50 -4.10 (-0.21%)
bluebird bio, Inc. (BLUE)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 3.2000 |
| Open | 3.2000 |
| Bid | 3.0000 x 4000 |
| Ask | 3.0400 x 4000 |
| Day's Range | 3.0400 - 3.2300 |
| 52 Week Range | 2.7800 - 8.5800 |
| Volume | |
| Avg. Volume | 4,195,020 |
| Market Cap | 325.137M |
| Beta (5Y Monthly) | 0.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BLUE
Related Research
- bluebird bio, Inc.Analyst Report: Incyte CorporationIncyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.RatingFair ValueEconomic Moat4 days agoMorningstar
- Motley Fool
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12 months. CRISPR Therapeutics doesn't have any approved treatments on the market yet, but that'll change soon enough, which is the crux of the thesis in favor of it being a great growth stock. Through its partnership with Vertex Pharmaceuticals, it's aiming to commercialize the gene therapy exa-cel, which was developed to provide a functional cure for both beta-thalassemia and sickle cell disease.
- Motley Fool
More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics
Gene editing is a relatively new technology that allows scientists to modify an organism's DNA. Two companies that are hard at work in this field are Bluebird Bio (NASDAQ: BLUE) and CRISPR Therapeutics (NASDAQ: CRSP). Bluebird Bio currently has two approved gene-editing therapies on the market.
- Motley Fool
2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street
Investors looking for stocks that can put up dramatic gains in a short amount of time naturally flock to biotech stocks. Up and down Wall Street, the investment bank analysts have been telling anyone who'll listen to buy these biotech stocks before they soar. The average price target on these stocks suggests some dramatic gains could be up ahead.
